Lexeo Therapeutics (LXEO) is highlighted as one of billionaire Daniel Sundheim’s stock picks with significant upside potential. Leerink recently adjusted the price target on Lexeo Therapeutics from $20 to $18 while maintaining an Outperform rating. The company recently raised $135 million through a secondary offering and private placement, bolstering its financial position for upcoming trials. Lexeo Therapeutics specializes in developing gene therapies for cardiovascular diseases and Alzheimer’s.

Read more at Yahoo Finance: Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential